Background: Pathological tricuspid regurgitation is often secondary, resulting from the left-sided heart disease. The need for correction of tricuspid regurgitation is usually considered at the time of surgical correction of the left-sided valve lesions Methods: We examined the incidence of tricuspid regurgitation in 60 patients with mitral valve disease, indicated for mitral valve surgery in our center, in the period from 2009 to 2012. We evaluated which of these accompanying conditions follow severe tricuspid regurgitation (atrial fibrillation, huge left atrium, dilated tricuspid annulus, left ventricular dysfunction). Results: The results showed that 33% of all patients undergoing mitral valve surgery had tricuspid valve surgery. 65% of them had severe and 35% had moderate tricuspid regurgitation. 38% of all patients (with and without tricuspid valve surgery) had moderate tricuspid regurgitation; 31% of patients with moderate tricuspid regirgitation had tricuspid valve surgery, 69% of them did not have tricuspid valve surgery. In patients with severe tricuspid regurgitation we found higher frequency of atrial fibrillation (p=0.013), tricuspid an-
;11(3-4):101.
VII. nacionalni sastanak o kardiovaskularnim intervencijama s međunarodnim sudjelovanjem VI. sastanak intervencijskih kardioloških medicinskih sestara i tehničaraThere are conflicting evidence regarding the use of intra-aortic balon pump (IABP) in acute coronary syndrome and shock patients. 1,2 Current European Society of Cardiology (ESC) Guidelines does not recommend IABP to be routinely used. It is intended to be used in patients with non ST-segment elevation myocardial infarction (NSTEMI) with acute mechanical complications. ESC Guidelines considered meta-analyses by Sjauw el al and the major randomized clinical trial IABP SHOCK II. This research did not confirm degraded mortality 30 days after ST-segment elevation myocardial infarction (STEMI) with shock. There are several flaws to this study: the absence of long-term survival, not taking into account patients with mechanical complications of myocardial infarction, NSTEMI patients and cardiogenic shock after 12 hours. 50% of patients had blood pressure ≥ 90 mmHg, which rise the question of inclusion criteria. However, meta-analyses showed significant reduction in mortality in cardiogenic shock after STEMI in patients treated with thrombolysis and IABP, but without primary percutaneous coronary intervention. New randomized clinical trials are needed, so that a definite conclusion on long-term survival could be made, as well to establish if there are groups within those patients, which could benefit from the use of IABP.We present our IABP experience, in University Hospital Centre Osijek, in time period from 2014 to 2015, in acute coronary syndrome patients and cardiogenic shock, and their short term outcome and survival. This is ongoing study planned to follow long term outcome as well.
Zorin
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.